A Phase 1/2 interventional study of BIIB147 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Biogen. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Biogen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Amyotrophic Lateral Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · Biogen.
Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, this one is one of 2 that started in 2026, is one of 2 in phase 1/2, and was the 11th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →2 of the 11 studies in Amyotrophic Lateral Sclerosis by Biogen are open now, in 1 country. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 69 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 99 across the 9 interventional studies, 132 across the 2 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
2 of the studies in Amyotrophic Lateral Sclerosis by Biogen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07223723BiogenA Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS) | 2027-05-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, researchers will learn more about the effects of BIIB147, in participants with amyotrophic lateral sclerosis, also known as ALS. ALS is a rare disease that damages the motor neurons in the brain and spinal cord that help control the movement of muscles in the body. It is a progressive disease, which means that it gets worse with time. Over time, this causes increasing problems with speaking, swallowing, moving the arms and legs, and breathing. In the case of ALS, this eventually leads to death from patients not being able to breathe.
This is a "first-in-human" study. This means that this study drug will be given to people for the very first time in this study. These studies are important because they help researchers learn about the safety of the study drug, how the body processes it, and what dose might be appropriate before testing it in larger groups.
The main goal of the study is to learn about the safety of BIIB147 in adult participants with ALS. The main question researchers want to answer is:
Researchers will also learn more about:
This study will be done as follows:
The primary objectives of this study are to evaluate the safety and tolerability of BIIB147 during the MAD Period and the long-term safety and tolerability of BIIB147 during the Open Label Extension (OLE) and the Integrated MAD and OLE Periods.
The secondary objectives of MAD Period are to evaluate the pharmacokinetics (PK) profile of total active BIIB147 related species in serum and cerebrospinal fluid (CSF), and to evaluate the impact of BIIB147 on neurodegeneration. The secondary objective for the OLE is to evaluate the long-term PK profile of total active BIIB147 related species in serum and CSF. The secondary objectives of the Integrated MAD Period and OLE are to evaluate the long-term impact of BIIB147 on neurodegeneration, on clinical outcomes of disease progression and survival for participants with earlier initiation of BIIB147 (i.e., start of MAD), compared with delayed initiation of BIIB147 (i.e., at start of the OLE), and long-term PK profile of total active BIIB147 related species in serum and CSF.
Key Inclusion Criteria:
MAD Period
OLE
Key Exclusion Criteria:
MAD Period
OLE
Note: Other protocol-defined Inclusion/Exclusion criteria do apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will either receive Dose A of BIIB147 or a placebo for 12 weeks.
Drug: BIIB147 · Drug: Placebo
Participants will either receive Dose B of BIIB147 or a placebo for 12 weeks.
Drug: BIIB147 · Drug: Placebo
Participants will either receive Dose C of BIIB147 or a placebo for 12 weeks.
Drug: BIIB147 · Drug: Placebo
Participants will either receive Dose D of BIIB147 or a placebo for 20 weeks.
Drug: BIIB147 · Drug: Placebo
Participants from Cohorts A-D who complete the MAD period will enter a 4-week blinded loading-dose period. During this period, participants randomized to BIIB147 in the MAD period will receive placebo, followed by BIIB147, while participants randomized to placebo during the MAD period will receive BIIB147. Upon completion of the blinded loading-dose period, all participants will enter the open-label maintenance dose period and receive BIIB147 for up to 340 weeks.
Drug: BIIB147 · Drug: Placebo
Administered intrathecally (IT)
Administered IT
MAD, OLE, Integrated MAD and OLE Periods: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Up to Week 416
MAD, OLE, Integrated MAD and OLE Periods: Serum Concentrations of Total Active BIIB147 Related Species
Time frame: Pre-dose and at multiple time points post-dose [MAD: Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D); OLE and Integrated MAD and OLE: Up to Week 340
MAD, OLE, Integrated MAD and OLE Periods: Cerebrospinal Fluid (CSF) Concentrations of Total Active BIIB147 Related Species
Time frame: Pre-dose at multiple timepoints [MAD: Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D); OLE and Integrated MAD and OLE: Up to Week 340]
MAD Period: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of BIIB147
Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]
MAD Period: Area Under the Serum Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC0-last) of BIIB147
Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]
MAD Period: Maximum Observed Serum Concentration (Cmax) of BIIB147
Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]
MAD Period: Time to Reach Maximum Observed Serum Concentration (Tmax) of BIIB147
Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]
MAD Period: Elimination Half-Life (t1/2) of BIIB147
Time frame: Pre-dose and at multiple time points post-dose [Up to Week 16 (Cohorts A, B, and C) and Up to Week 24 (Cohort D)]
MAD, Integrated MAD and OLE Periods: Change From Baseline in Plasma Concentration of Neurofilament Light Chain (NfL)
Time frame: Baseline, Week 16 (Cohorts A, B, and C), Week 24 (Cohort D), and Up to Week 340 (Integrated MAD and OLE)
Integrated MAD and OLE Period: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score
Time frame: Baseline, Up to Week 340
Integrated MAD and OLE Period: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC)
Time frame: Baseline, Up to Week 340
Integrated MAD and OLE Period: Change From Baseline in Muscle Strength as Measured by Handheld Dynamometry (HHD)
Time frame: Baseline, Up to Week 340
Integrated MAD and OLE Period: Change From Baseline in Bulbar Strength as Measured by Iowa Oral Pressure Instrument (IOPI)
Time frame: Baseline, Up to Week 340
Integrated MAD and OLE Period: Change From Baseline in Rasch Overall Amyotrophic Lateral Sclerosis (ALS) Disability (ROADS).
Time frame: Baseline, Up to Week 340
Integrated MAD and OLE Period: Change From Baseline in Weight
Time frame: Baseline, Up to Week 340
Integrated MAD and OLE Period: Time to Death or Permanent Ventilation
Permanent ventilation is defined as ≥ 22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥ 21 consecutive days.
Time frame: Up to Week 416
Integrated MAD and OLE Period: Time to Death
Time frame: Up to Week 416
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jan 2034, 87 months after the start.
Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 87 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →